



Company Announcement no. 5/2016

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 31 March 2016

Veloxis announces the total number of shares and voting rights in the company as of 31 March 2016

Veloxis Pharmaceuticals A/S announces in accordance with Section 6 of the *Danish Statutory Order on Issuers' Disclosure Obligations*, the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.

With reference to Company Announcement no. 4 / 2016 dated 30 March 2016 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Veloxis as of 31 March 2016.

Date	Total number of shares (nominal value of DKK 0.10 each)	Share capital (nominal value in DKK)	Total number of votes
31 March 2016	1,685,506,541	168,550,654.10	1,685,506,541

For more information, please contact:

Craig A. Collard
President & CEO
Phone: +1 919 524 4317
Email: cac@veloxis.com

Johnny Stilou
EVP, Chief Financial Officer
Phone: +45 30 53 33 64
Email: jst@veloxis.com

Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.